Financial Performance - The company's operating revenue for 2019 was CNY 871,896,072.63, representing a 65.08% increase compared to CNY 528,171,162.26 in 2018[21] - The net profit attributable to shareholders for 2019 was CNY 306,801,352.58, which is an increase of 111.31% from CNY 145,187,507.20 in the previous year[21] - The net profit excluding non-recurring gains and losses was CNY 297,626,223.40, up 116.08% from CNY 137,738,034.86 in 2018[21] - Basic earnings per share increased by 110.26% to CNY 1.64 in 2019 compared to CNY 0.78 in 2018[22] - The weighted average return on equity rose to 33.50%, an increase of 13.97 percentage points from 19.53% in 2018[22] - The company achieved a net profit of CNY 31,934,044.93 in Q1 2019, which increased to CNY 121,613,658.42 by Q3 2019[23] - The company reported a total revenue of CNY 137,087,304.22 in Q1 2019, increasing to CNY 270,306,816.79 by Q4 2019[23] - The company reported a total revenue of 1.2 billion in 2019, reflecting a year-over-year growth of 15%[104] - The company reported a total revenue of 2,001.812 million yuan for the year 2019, reflecting a growth of 11.35% compared to the previous year[115] - The company achieved a revenue of 851 million yuan in 2019, representing a year-on-year growth of 75.09%[94] Cash Flow and Assets - Cash flow from operating activities for 2019 was CNY 240,066,206.82, a 77.65% increase from CNY 135,131,582.68 in 2018[21] - Total assets at the end of 2019 reached CNY 1,189,296,891.60, a 32.53% increase from CNY 897,381,513.43 at the end of 2018[21] - Cash and cash equivalents increased significantly to CNY 241,164,711.77 from CNY 54,239,819.48 in 2018, representing a growth of 344%[183] - The company reported a net increase in cash and cash equivalents of CNY 168,635,901.59, contrasting with a decrease of CNY 49,799,842.42 in the previous year[196] - The total cash inflow from operating activities reached CNY 695,961,521.20, up from CNY 458,683,815.63 in the previous year, representing a growth of 51.8%[194] Research and Development - The company's R&D expenses increased by 46.94% to 28,137,898.34 CNY, reflecting a commitment to innovation[46] - Research and development expenses for 2019 amounted to CNY 28,137,898.34, compared to CNY 19,149,686.19 in 2018, indicating a 47% increase[187] - The number of R&D personnel was 69, making up 8.66% of the total workforce, highlighting the company's commitment to innovation[59] - The management team emphasized the importance of technological advancements, with a 10% increase in R&D investment planned for 2020, totaling 120 million RMB[151] Market Position and Products - The company’s main business involves the research, production, and sales of isothiazolinone industrial biocides and chlorobenzonitrile chemical intermediates[29] - The company has established stable long-term partnerships with major clients such as Dow Chemical and Lanxess, enhancing its market position in the industrial biocide sector[34] - The company is the largest producer of isothiazolinone industrial biocides in China, with a significant market share[90] - The company plans to expand its product line by initiating a project for the annual production of 2,000 tons of dye intermediates[44] - The company’s BIT series products have been successfully developed, filling a gap in its product range and allowing for customized services in collaboration with clients[35] Environmental Compliance and Sustainability - The company emphasizes environmental protection and has implemented clean production and recycling concepts in its manufacturing processes, ensuring compliance with environmental standards[36] - The company has reported compliance with environmental regulations, being classified as a key pollutant discharge unit[116] - The company has established a complete environmental management system, with regular monitoring of wastewater and air emissions, ensuring compliance with environmental regulations[127] - The company has committed to social responsibility initiatives, including environmental protection measures, as part of its operational strategy[116] Shareholder and Dividend Information - The company plans to distribute a cash dividend of CNY 6 per 10 shares, totaling CNY 112,005,600, and to increase capital by 4 shares for every 10 shares held[5] - In 2019, the company distributed a cash dividend of 6.00 RMB per 10 shares, totaling 112,005,600.00 RMB, with a net profit distribution ratio of 36.51%[102] - In 2018, the cash dividend was 3.90 RMB per 10 shares, totaling 72,803,640.00 RMB, with a net profit distribution ratio of 50.14%[102] Strategic Outlook and Future Plans - The company provided a future outlook, projecting a revenue growth of 10% for the next fiscal year[104] - The company is actively seeking new fine chemical products to diversify its business structure and mitigate economic risks[93] - The company plans to achieve a revenue of 1 billion yuan in 2020, focusing on stable production and operation of industrial biocides[95] - The company is considering strategic acquisitions to enhance its market position, with a budget of 200 million allocated for potential deals[104] Audit and Compliance - The audit report issued by Da Hua Certified Public Accountants confirmed the accuracy and completeness of the financial statements[4] - The company appointed Dahua Accounting Firm (Special General Partnership) for the 2019 annual audit, with an audit fee of RMB 430,000[108] - There were no major litigation or arbitration matters during the reporting period[109] - The company has no significant changes in accounting policies or estimates during the reporting period[109] Employee and Management Information - The total number of employees in the parent company and major subsidiaries is 797, with 543 in production, 29 in sales, 70 in technology, 16 in finance, and 139 in administration[157] - The total remuneration for directors and senior management was reported at 14,377,000 RMB[149] - The company has a structured approach to assess and determine the remuneration of its senior management[156]

2019 年第三季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2019 年第三季度报告 1 / 22 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2019 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人刘宪武、主管会计工作负责人王希梁及会计机构负责人（会计主管人员）刘东光 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末 | | | --- | --- | --- | --- | --- | | | | | 增减(%) | | | 总资产 | 1, ...

Financial Performance - The company's operating revenue for the first half of 2019 was approximately ¥349.89 million, representing a 38.81% increase compared to ¥252.06 million in the same period last year[18]. - The net profit attributable to shareholders for the first half of 2019 was approximately ¥112.56 million, a significant increase of 78.42% from ¥63.09 million in the previous year[18]. - The net cash flow from operating activities for the first half of 2019 was approximately ¥82.99 million, which is a 13.00% increase compared to ¥73.45 million in the same period last year[19]. - The total assets at the end of the reporting period were approximately ¥1.08 billion, reflecting a 20.68% increase from ¥897.38 million at the end of the previous year[19]. - The net assets attributable to shareholders at the end of the reporting period were approximately ¥911.90 million, which is a 14.08% increase from ¥799.34 million at the end of the previous year[19]. - The basic earnings per share for the first half of 2019 were ¥0.60, up 76.47% from ¥0.34 in the same period last year[20]. - The weighted average return on equity for the first half of 2019 was 13.16%, an increase of 4.37 percentage points compared to 8.79% in the previous year[20]. - The company achieved operating revenue of 349.89 million yuan, a year-on-year increase of 38.81%, and a net profit attributable to shareholders of 112.56 million yuan, up 78.42% compared to the same period last year[34]. Production and Capacity - The company has achieved a total production capacity of 30,000 tons for isothiazolinone industrial biocides following the completion of expansion projects in Q2 and Q3 of 2019[31]. - The production capacity for CIT/MIT series products increased by 12,000 tons/year and BIT series products by 2,500 tons/year, contributing to a significant growth in revenue from the industrial biocide business[36]. - The production of industrial biocides saw a volume increase of 53.87% and a production increase of 53.09% year-on-year, alleviating previous capacity constraints[36]. Research and Development - The company has a robust R&D framework, holding 16 invention patents and 8 utility model patents, which supports its production cost control and product quality assurance[31]. - The company’s R&D expenses increased by 132.38% to 7.68 million yuan, reflecting a greater investment in new processes and products[43]. - Research and development expenses increased to ¥7,675,496.89, up 132.5% from ¥3,302,990.26 in the previous year[102]. Environmental Compliance - The company emphasizes environmental protection and has invested in advanced production and waste treatment facilities to meet national and local standards[31]. - The company reported a chemical oxygen demand (COD) discharge of 1.6613 tons and ammonia nitrogen discharge of 0.3415 tons in the first half of 2019[65]. - The total nitrogen discharge was recorded at 0.6429 tons, with a continuous discharge of sulfur dioxide at 0.11535 tons and nitrogen oxides at 0.3853 tons[65]. - The company has not reported any major environmental violations, demonstrating commitment to sustainability[64]. - The company adheres to the Liaoning Provincial Wastewater Comprehensive Discharge Standard (DB21-1627-2008) for wastewater treatment[67]. Shareholder Information - The company has a total of 8,224 common stock shareholders as of the end of the reporting period[81]. - The top two shareholders, Dalian Sanxin Investment Co., Ltd. and Dalian Tongyun Investment Co., Ltd., each hold 30.00% of the shares, totaling 55,995,034 shares[83]. - The total number of shares held by the top ten unrestricted shareholders amounts to 25,000,000 shares, with the largest individual shareholder being Zhang Zhijian, holding 4,508,519 shares (2.42%)[84]. Financial Position - The company reported a total liability of CNY 171,063,736.68, up from CNY 99,348,013.33, indicating an increase of about 72.1%[95]. - The total equity attributable to shareholders increased to CNY 911,900,163.38 from CNY 799,343,117.50, representing a growth of approximately 14.1%[95]. - The company reported a total of 112,557,286.63 RMB in comprehensive income for the current period[119]. Risk Factors - The company faces risks related to core technology leakage and talent loss, which could adversely affect production and sustainable development[52]. - Environmental protection risks are heightened due to the company's classification as a heavily polluting industry, with potential increases in compliance costs impacting profitability[52]. - The company is facing risks related to the underutilization of production capacity from new projects, which may not reach full production as planned due to various operational challenges[54]. Corporate Governance - The company did not propose any profit distribution or capital reserve transfer to share capital during the reporting period[4]. - There were no non-operating fund occupations by controlling shareholders or related parties during the reporting period[6]. - The company has not made any changes to its accounting firm during the audit period, maintaining consistency in financial reporting[61]. Tax Management - The company aims to manage its deferred tax assets and liabilities effectively to optimize tax positions[200]. - The management of deferred tax assets and liabilities is a key component of the company's overall financial strategy[200].

Financial Performance - The company's operating revenue for 2018 was RMB 528,171,162.26, representing a 28.71% increase compared to RMB 410,364,502.50 in 2017[21] - The net profit attributable to shareholders of the listed company reached RMB 145,187,507.20, a 44.80% increase from RMB 100,266,398.87 in the previous year[21] - The net profit attributable to shareholders after deducting non-recurring gains and losses was RMB 137,738,034.86, up 50.16% from RMB 91,726,600.68 in 2017[21] - Cash flow from operating activities amounted to RMB 135,131,582.68, reflecting a 77.71% increase compared to RMB 76,038,489.56 in the previous year[21] - Total assets at the end of 2018 were RMB 897,381,513.43, a 15.15% increase from RMB 779,330,217.36 at the end of 2017[21] - Net assets attributable to shareholders of the listed company increased to RMB 799,343,117.50, a 16.26% rise from RMB 687,543,010.40 in 2017[21] - Basic earnings per share increased by 39.29% to CNY 0.78 in 2018 compared to CNY 0.56 in 2017[22] - The weighted average return on equity rose to 19.53%, an increase of 4.59 percentage points from 14.94% in 2017[22] - The company achieved operating revenue of CNY 528.17 million and net profit attributable to shareholders of CNY 145.19 million, representing growth of 28.71% and 44.80% respectively compared to 2017[40] - The company achieved a total revenue of CNY 528.17 million in the reporting period, representing a year-on-year growth of 28.71%[46] - The net profit attributable to shareholders was CNY 145.19 million, reflecting a significant increase of 44.80% compared to the previous year[46] Dividend Policy - The company plans to distribute a cash dividend of RMB 3.90 per 10 shares, totaling RMB 72,803,640.00[5] - In 2018, the company distributed cash dividends amounting to 72,803,640 RMB, representing 50.14% of the net profit attributable to shareholders[107] - The cash dividend policy stipulates that at least 20% of the distributable profit should be allocated for dividends when the net profit is positive[105] Operational Highlights - The sales revenue from isothiazolinone-based industrial biocides remains the primary source of income, with an increased contribution from F-cyano intermediates due to partial production from fundraising projects[30] - The CIT/MIT series products are widely used in industrial circulating water and oilfield water injection, contributing significantly to revenue[30] - The industrial biocide business generated revenue of CNY 481.58 million, with a year-on-year growth of 20.02%, while sales volume and production volume increased by 6.90% and 4.47% respectively[40] - The company’s production capacity for isothiazolinone biocides reached 30,000 tons after the completion of the fundraising project, significantly enhancing its market position as the largest producer in China[36] - The company’s comprehensive capacity utilization rate for biocide products reached 98.13%, indicating a supply-demand imbalance that remains a challenge until new capacity is operational[40] - The company has established long-term stable partnerships with international chemical giants such as Dow Chemical and Lanxess, expanding its international sales presence across multiple continents[33] - The company’s BIT series production capability was established with the completion of the fundraising project, enhancing its product portfolio and addressing previous gaps in its offerings[43] - The company’s revenue from the important subsidiary, Shenyang Bai'ao, improved significantly, with losses reduced by CNY 15.43 million compared to the previous year[40] Research and Development - Research and development expenses amounted to CNY 19.15 million, accounting for 3.63% of total revenue, with 67 R&D personnel representing 10.60% of the total workforce[60] - The company holds 15 invention patents and 8 utility model patents, showcasing its commitment to technological innovation and cost control[36] - The company has established a technology center to optimize production processes and develop new products, enhancing its competitive edge in the market[74] Environmental Compliance - The company has a strong focus on environmental protection, ensuring compliance with national and local environmental standards, which is a key competitive advantage[38] - The wastewater treatment facility at Songmu Island subsidiary has a design capacity of 800 tons/day and has been in continuous operation since 2011[131] - The chemical oxygen demand (COD) emissions from Songmu Island subsidiary were 57.1258 tons generated with 3.3502 tons discharged, meeting standards[128] - The total nitrogen emissions from Songmu Island subsidiary were 2.9157 tons generated with 1.0208 tons discharged, meeting standards[128] - The hazardous waste generated at Songmu Island subsidiary included 157.55 tons of distillation residue, with 265.55 tons disposed of[128] - The company has implemented continuous operation of air pollution control facilities since 2011, with a design capacity of 2500 cubic meters/hour for various emissions[131] - The company has successfully completed environmental impact assessments for multiple projects, including the expansion of its CIT/MIT series product line[136] Market Expansion and Strategy - The company aims to expand its international market share, particularly in Europe and North America, where it currently holds a low market share[95] - The company plans to continue expanding its product lines and market presence in the biocide sector[30] - The company’s market expansion strategy includes participation in international trade shows and online marketing to attract new customers[33] - The company is considering strategic acquisitions to enhance its product portfolio, with a budget of 300 million allocated for potential deals[174] Financial Management - The company has approved the use of up to RMB 100 million of temporarily idle raised funds for cash management[120] - The company also approved the use of up to RMB 100 million of idle self-owned funds for cash management[120] - The company has invested RMB 10 million in bank financial products from raised funds, with an expected annualized return of 4.30%[122] - The company has invested RMB 5 million in self-owned funds in bank financial products, with an expected annualized return of 5.00%[122] Corporate Governance - The company has established a comprehensive compensation management system, ensuring compliance with national and local social security regulations[180] - The company has revised its governance structure and internal control systems in accordance with relevant laws and regulations[185] - The company has maintained a stable management team with no significant changes in personnel during the reporting period[170] - The company reported no changes in shareholding for the current and departing directors, supervisors, and senior management during the reporting period[167] Audit and Compliance - The audit report issued by Ruihua Certified Public Accountants was a standard unqualified opinion[4] - The audit report confirmed that the financial statements fairly reflect the company's financial position and operating results for the year ended December 31, 2018[195] - The audit firm confirmed its independence and adherence to professional ethics while conducting the audit[196] - The company did not have any significant internal control deficiencies reported during the audit period[190] Risks and Challenges - The company faces risks including core technology leakage, environmental protection compliance, and safety production issues[99][100] - The company is under scrutiny for environmental and safety regulations following the explosion, which may affect production operations[102] - The company’s F cyano intermediate and BIT product prices experienced significant fluctuations due to the March 21 explosion incident, impacting future earnings[101]

2019 年第一季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2019 年第一季度报告 1 / 19 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 6 | | 四、 | 附录 8 | 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 | | 本报告期末 | 上年度末 | 本报告期末比上年度末增 | | | --- | --- | --- | --- | --- | | | | | 减(%) | | | 总资产 | 985,072,287.93 | 897,381,513.43 | | 9.77 | | 归属于上市公司 | 831,296,255.63 | 799,343,117.50 | | 4.00 | | 股东的净资产 | | | | | | | 年初至报告期末 | 上年初至上年报 ...

2018 年第三季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2018 年第三季度报告 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2018 年第三季度报告 一、 重要提示 1.1 公司董事会、监事会及董事、监事、高级管理人员保证季度报告内容的真实、准确、完整， 不存在虚假记载、误导性陈述或者重大遗漏，并承担个别和连带的法律责任。 1.2 公司全体董事出席董事会审议季度报告。 1.3 公司负责人刘宪武、主管会计工作负责人王希梁及会计机构负责人（会计主管人员）刘东光 保证季度报告中财务报表的真实、准确、完整。 1.4 本公司第三季度报告未经审计。 二、 公司基本情况 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末 增减(%) 总资产 936,043,455.24 779,330,217.36 20.11% 归属于上市公司 股东的净资产 762,742,913.41 68 ...

Financial Performance - The company's operating revenue for the first half of 2018 was ¥252,056,841.71, representing a 31.96% increase compared to ¥191,015,251.35 in the same period last year[16]. - The net profit attributable to shareholders for the first half of 2018 was ¥63,086,840.98, up 15.53% from ¥54,607,121.92 in the previous year[16]. - The net cash flow from operating activities increased by 30.01%, reaching ¥73,447,130.06 compared to ¥56,492,478.96 in the same period last year[16]. - The company reported a net profit after deducting non-recurring gains and losses of ¥61,207,392.73, which is an 18.92% increase from ¥51,467,381.41 in the previous year[16]. - Basic earnings per share for the first half of 2018 were ¥0.34, a 17.24% increase from ¥0.29 in the same period last year[17]. - The company achieved a revenue of CNY 252.06 million, representing a year-on-year growth of 31.96%[34]. - The net profit attributable to shareholders was CNY 63.09 million, an increase of 15.53% compared to the previous year[29]. - The company reported a total profit for the current period of ¥75,995,151.83, compared to ¥64,399,800.51 in the previous period, marking an 18.5% increase[99]. - The company’s total comprehensive income for the current period was ¥62,931,421.39, compared to ¥54,592,620.93 in the previous period, reflecting an increase of 15.5%[99]. Assets and Liabilities - The company's total assets as of the end of the reporting period were ¥849,692,618.89, a 9.03% increase from ¥779,330,217.36 at the end of the previous year[16]. - Total liabilities amounted to CNY 100,339,712.58, up from CNY 92,908,732.45, which is an increase of around 8.5%[93]. - Owner's equity reached CNY 749,352,906.31, compared to CNY 686,421,484.91, showing a growth of about 9.2%[93]. - Cash and cash equivalents increased to CNY 222,077,606.84 from CNY 134,245,173.62, marking a significant rise of approximately 65.4%[91]. - Accounts receivable decreased to CNY 88,890,284.97 from CNY 99,832,727.64, a decline of about 11%[91]. - Inventory increased to CNY 49,505,854.01 from CNY 47,589,573.63, reflecting a growth of approximately 4%[91]. Production and Operations - The production capacity of the company's isothiazolinone-based biocides exceeded 10,000 tons, with plans to surpass 20,000 tons after future projects are completed[25]. - The company is actively advancing projects to increase production capacity for CIT/MIT and BIT series products, aiming for completion by the end of 2018[32]. - The company has maintained stable production without interruptions due to environmental issues, indicating effective operational management[29]. Research and Development - The company has a strong focus on R&D, with expenditures amounting to CNY 3.30 million, a 6.30% increase from the previous year[34]. Environmental Compliance - The company has established a complete environmental management system, conducting annual monitoring of wastewater and air emissions, with real-time data transmission to the environmental protection bureau[68]. - The company’s environmental protection measures are in compliance with the relevant standards, ensuring all emissions are within permissible limits[58]. - The company reported a continuous operation of wastewater treatment facilities with a design capacity of 800 tons/day since 2011[60]. - The company has implemented air pollution control facilities with a design capacity of 2500 cubic meters/hour, operational since 2011[60]. Shareholder Information - The total number of common shareholders at the end of the reporting period was 11,111[78]. - The top ten shareholders held a total of 133,333,334 shares, representing 100% of the total shares[80]. - Dalian Sanxin Investment Co., Ltd. and Dalian Tongyun Investment Co., Ltd. each held 38,666,667 shares, accounting for 29% of the total shares[80]. Risks and Challenges - The company faces risks from intensified domestic market competition, potential leakage of core technology, and environmental protection regulations[42][43]. Corporate Governance - The company experienced a change in its board of directors, with several new appointments made during the reporting period[87]. - The company reported no changes in the controlling shareholder or actual controller during the reporting period[86]. Accounting Policies - The accounting policies and estimates are in accordance with relevant enterprise accounting standards, particularly regarding revenue recognition[122]. - The company does not recognize changes in the fair value of equity instruments in profit or loss[154].

2018 年第一季度报告 公司代码：603360 公司简称：百傲化学 非经常性损益项目和金额 √适用 □不适用 单位：元 币种：人民币 大连百傲化学股份有限公司 2018 年第一季度报告 1 / 18 | 一、 | 重要提示 3 | | --- | --- | | 二、 | 公司基本情况 3 | | 三、 | 重要事项 5 | | 四、 | 附录 8 | 2018 年第一季度报告 一、 重要提示 二、 公司基本情况 2.1 主要财务数据 2018 年第一季度报告 | 家政策规定、按照一定标准定额或 | | | --- | --- | | 定量持续享受的政府补助除外 | | | 除同公司正常经营业务相关的有效 | 512,876.71 | | 套期保值业务外，持有交易性金融 | | | 资产、交易性金融负债产生的公允 | | | 价值变动损益，以及处置交易性金 | | | 融资产、交易性金融负债和可供出 | | | 售金融资产取得的投资收益 | | | 所得税影响额 | -124,219.55 | | 合计 | 703,910.78 | | | 购买银行理财产品收益 | 2.2 截止报告期末的股东总数、前十名股 ...

Financial Performance - The company's operating revenue for 2017 was CNY 410,364,502.50, representing a 5.37% increase compared to CNY 389,433,985.09 in 2016[21] - The net profit attributable to shareholders for 2017 was CNY 100,266,398.87, a 2.03% increase from CNY 98,273,387.87 in 2016[21] - Basic earnings per share decreased by 21.43% to CNY 0.77 in 2017 from CNY 0.98 in 2016[22] - The weighted average return on equity fell by 9.04 percentage points to 14.94% in 2017 compared to 23.98% in 2016[22] - Total revenue for Q4 2017 was CNY 113,966,237.49, with a net profit attributable to shareholders of CNY 18,796,922.05[24] - The total amount of non-recurring gains and losses for 2017 was CNY 8,539,798.19, compared to CNY 5,208,449.76 in 2016[27] - The company achieved operating revenue of CNY 410.36 million, representing a year-on-year growth of 5.37%[44] - The net profit attributable to shareholders was CNY 100.27 million, an increase of 2.03% compared to the previous year[44] Cash Flow and Investments - The net cash flow from operating activities decreased by 36.51% to CNY 76,038,489.56 in 2017 from CNY 119,767,902.83 in 2016[21] - The net cash flow from operating activities was negative CNY 245,565.62 in Q4 2017 due to increased raw material procurement costs[24] - The net cash flow from investing activities showed a drastic increase of 3955.62%, amounting to -$117,559,136.82, attributed to the construction expenditures of fundraising projects[62] - The net cash flow from financing activities increased significantly due to public stock issuance, resulting in a net cash inflow of $51,203,636.53[63] Assets and Liabilities - The total assets at the end of 2017 were CNY 779,330,217.36, a 24.42% increase from CNY 626,367,873.82 at the end of 2016[21] - The net assets attributable to shareholders increased by 49.83% to CNY 687,543,010.40 at the end of 2017 from CNY 458,889,228.75 at the end of 2016[21] - Total current assets increased to CNY 425,178,149.10 from CNY 264,148,380.78, representing a growth of approximately 60.9%[197] - Total liabilities decreased to CNY 92,908,732.45 from CNY 168,276,804.77, a reduction of about 55.2%[199] - Total equity increased to CNY 686,421,484.91 from CNY 458,091,069.05, showing an increase of approximately 49.8%[199] Shareholder Information - The company plans to distribute a cash dividend of CNY 2.5 per 10 shares, totaling CNY 33,335,000.00[5] - The company issued 33.34 million shares in 2017, increasing total shares from 10 million in 2016 to 13.34 million[22] - The total number of ordinary shareholders increased from 11,366 to 12,450 during the reporting period, showing a growth of 9.54%[145] - The top two shareholders, Dalian Sanxin Investment Co., Ltd. and Dalian Tongyun Investment Co., Ltd., each hold 29% of the shares, totaling 38,666,667 shares[147] Research and Development - The company has invested significantly in R&D, with expenditures amounting to CNY 15.17 million, a growth of 8.38% from the previous year[46] - The total R&D expenditure was $15,166,475.66, accounting for 3.70% of total revenue, with 71 R&D personnel representing 14.52% of the total workforce[61] - The company is committed to increasing R&D investment, aiming to raise the proportion of R&D expenses in sales revenue[96] Market and Production - The company specializes in the research, production, and sales of isothiazolinone-based industrial biocides, with a focus on various applications across multiple industries[29] - The market for isothiazolinone biocides is expected to expand further with new applications in aquaculture, agricultural films, and veterinary medicine[33] - The company maintained a high level of production capacity utilization, with no production interruptions due to environmental inspections or safety incidents[39] - The production capacity for isothiazolinone raw materials is expected to exceed 20,000 tons after the completion of future investment projects[34] Risks and Compliance - The company has outlined various risks in its report, which investors should consider[7] - The company faces risks from intensified domestic market competition due to the promotion of environmentally friendly biocides, which may attract new competitors and lead to increased production capacity among existing players[98] - There is a risk of core technology leakage and talent loss, which could adversely affect the company's production and sustainable development, given its leading position in the production of isothiazolinone industrial biocides[98] - The company operates in a heavily polluting industry, facing environmental protection risks that could increase operational costs and impact profitability due to stricter regulations[98] Environmental Management - The company has established various pollution prevention facilities, including wastewater treatment facilities with a design capacity of 800 tons per day, which are in continuous operation[123] - The company has completed environmental impact assessments for several projects, including the CIT/MIT series product reconstruction project, which has been accepted[125] - The company has established a complete environmental management system, including annual monitoring of wastewater and air emissions[132] Corporate Governance - The report includes a standard unqualified audit opinion from Ruihua Certified Public Accountants[4] - The company appointed Ruihua Certified Public Accountants as the auditor for the 2017 fiscal year, with a remuneration of 3.4 million RMB[113] - The company has not faced any risks of suspension or termination of its listing status[114] - The company has established measures to ensure fair pricing in unavoidable related transactions[109]

2017 年第三季度报告 公司代码：603360 公司简称：百傲化学 大连百傲化学股份有限公司 2017 年第三季度报告 1 / 21 | 目录 | | --- | | 一、 | 重要提示 | 3 | | --- | --- | --- | | 二、 | 公司基本情况 | 3 | | 三、 | 重要事项 | 6 | | 四、 | 附录 | 9 | 2017 年第三季度报告 2.1 主要财务数据 单位：元 币种：人民币 本报告期末 上年度末 本报告期末比上年度末增 减(%) 总资产 756,348,161.60 626,367,873.82 20.75 归属于上市公司 股东的净资产 668,726,136.44 458,889,228.75 45.73 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减(%) 经营活动产生的 现金流量净额 76,284,055.18 81,470,380.61 -6.37 年初至报告期末 （1-9 月） 上年初至上年报告期末 （1-9 月） 比上年同期增减 （%） 营业收入 296,398,265.01 293,977,111.92 0.82 ...